NCT03762850Phase 3Completed

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

Study sponsor: Travere Therapeutics, Inc. · TVTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-08-07Actual
Enrollment · participants406Actual
Source updated2026-10-14Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview